Ensign Peak Advisors
LEGN icon

Ensign Peak Advisors’s Legend Biotech LEGN Stock Holding History

Ensign Peak Advisors’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$95.3K Sell
3,300
-650
-16% -$17.5K ﹤0.01% 1628
2026
Q1 		$71.5K Sell
3,950
-400
-9% -$7.63K ﹤0.01% 1637
2025
Q4 		$94.6K Hold
4,350
– – ﹤0.01% 1584
2025
Q3 		$142K Sell
4,350
-1,950
-31% -$72K ﹤0.01% 1675
2025
Q2 		$224K Sell
6,300
-2,750
-30% -$89.1K ﹤0.01% 1675
2025
Q1 		$307K Buy
9,050
+1,200
+15% +$43K ﹤0.01% 1640
2024
Q4 		$255K Hold
7,850
– – ﹤0.01% 1688
2024
Q3 		$383K Hold
7,850
– – ﹤0.01% 1660
2024
Q2 		$348K Hold
7,850
– – ﹤0.01% 1670
2024
Q1 		$440K Hold
7,850
– – ﹤0.01% 1650
2023
Q4 		$472K Hold
7,850
– – ﹤0.01% 1666
2023
Q3 		$527K Hold
7,850
– – ﹤0.01% 1572
2023
Q2 		$542K Hold
7,850
– – ﹤0.01% 1613
2023
Q1 		$379K Buy
7,850
+2,700
+52% +$132K ﹤0.01% 1686
2022
Q4 		$257K Sell
5,150
-250
-5% -$12.1K ﹤0.01% 1723
2022
Q3 		$220K Buy
5,400
+3,300
+157% +$155K ﹤0.01% 1843
2022
Q2 		$116K Hold
2,100
– – ﹤0.01% 1933
2022
Q1 		$76K Buy
2,100
+200
+11% +$7.9K ﹤0.01% 2076
2021
Q4 		$89K Buy
+1,900
New +$96.4K ﹤0.01% 2079

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Ensign Peak Advisors's LEGN Position: Q2 2026 in Review

Ensign Peak Advisors reduced its Legend Biotech (LEGN) stake by 16% in Q2 2026, selling an estimated $17.5K and leaving 3,300 shares worth $95.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1628.

Ensign Peak Advisors first reported a position in LEGN in Q4 2021 and has held it in 19 quarters since. The position peaked at $542K in Q2 2023. 218 funds tracked by Wall St. Rank hold LEGN as of Q2 2026.

  • Ensign Peak Advisors held 3,300 shares of Legend Biotech worth $95.3K as of Q2 2026.
  • Ensign Peak Advisors sold 650 Legend Biotech shares in Q2 2026, an estimated $17.5K.
  • Legend Biotech made up ﹤0.01% of Ensign Peak Advisors's portfolio in Q2 2026, its #1628 holding.
  • Ensign Peak Advisors first reported a position in Legend Biotech in Q4 2021 and has held it in 19 quarters since.
  • Ensign Peak Advisors's Legend Biotech position peaked at $542K in Q2 2023.
  • 218 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.